Enjaymo

Chemical Namesutimlimab-jome
Dosage FormInjection (intravenous; 1,100 mg/22 mL (50 mg/mL))
Drug ClassInhibitors
SystemBlood
CompanyBioverativ
Approval Year2022

Indication

  • Indicated to decrease the need for red blood cell (RBC) transfusion due to hemolysis in adults with cold agglutinin disease (CAD)
Last updated on 2/11/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Enjaymo (sutimlimab-jome) Prescribing Information. 2022Bioverativ USA Inc., Waltham, MA
Document TitleYearSource
Sutimlimab in cold agglutinin disease.2021The New England Journal of Medicine